Existing and emerging smoking cessation options for people with schizophrenia spectrum disorders

References

• Fiore F, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, Dorfman SF, Froelicher ES, Goldstein MG, Healton CG, et al. Treating tobacco use and dependence. Respir Care. 2008;53(9):1217–22.
   PubMed Web of Science ®Google Scholar
• Cahill K, Stevens S, Lancaster T. Pharmacological treatments for smoking cessation. JAMA. 2014;311:193–194. doi:10.1001/jama.2013.283787.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services (UDHHS). The health consequences of smoking–50 years of progress: A report of the surgeon general. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Vital Signs: Current cigarette smoking among adults aged ≥18 years with mental illness—United States, 2009–2011. Morbidity Mortal Weekly Rep. 2013;62:81–87.
   PubMed Web of Science ®Google Scholar
• Keltner NL, Grant JS. Smoke, smoke, smoke that cigarette. Perspect Psychiat Care. 2006;42:256–261. doi:10.1111/j.1744-6163.2006.00085.x.
   PubMed Web of Science ®Google Scholar
• De Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005;76:135–157. doi:10.1016/j.schres.2005.02.010.
   PubMed Web of Science ®Google Scholar
• Ashton M, Rigby A, Galletly C. Do population-wide tobacco control approaches help smokers with mental illness? Aust N Z J Psychiatry. 2014;48:121–123. doi:10.1177/0004867413502093.
   PubMed Web of Science ®Google Scholar
• Prochaska JJ. Smoking and mental illness- breking the link. N Engl J Med. 2011;365:196–198. doi:10.1056/NEJMp1105248.
   PubMed Web of Science ®Google Scholar
• Auquier P, Lançon C, Rouillon F, Lader M. Mortality in schizophrenia. Pharmacoepidem Drug Safe. 2007;16:1308–1312. doi:10.1002/pds.1496.
   PubMed Web of Science ®Google Scholar
• Aubin H-J, Rollema H, Svensson TH, Winterer G. Smoking, quitting, and psychiatric disease: a review. Neurosci Biobehav Rev. 2012;36:271–284. doi:10.1016/j.neubiorev.2011.06.007.
   PubMed Web of Science ®Google Scholar
• Addington J, el-Guebaly N, Campbell W, Hodgins DC, Addington D. Smoking cessation treatment for patients with schizophrenia. Am J Psychiatry. 1998;155:974–976. doi:10.1176/ajp.155.7.974.
   PubMed Web of Science ®Google Scholar
• Baker TB, Mermelstein R, Collins LM, Piper ME, Jorenby DE, Smith SS, Christiansen BA, Schlam TR, Cook JW, Fiore MC. New methods for tobacco dependence treatment research MPH, MBA. Ann Behav Med. 2011;41:192–207. doi:10.1007/s12160-010-9252-y.
   PubMed Web of Science ®Google Scholar
• Baker A, Richmond R, Haile M, Lewin TJ, Carr VJ, Taylor RL, Jansons S, Wilhelm K. A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. Am J Psychiatry. 2006;163:1934–1942. doi:10.1176/ajp.2006.163.11.1934.
   PubMed Web of Science ®Google Scholar
• Barr RS, Culhane MA, Jubelt LE, Mufti RS, Dyer MA, Weiss AP, Deckersbach T, Kelly JF, Freudenreich O, Goff DC. The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and non psychiatric controls. Neuropsychopharmacol. 2008;33:480–490. doi:10.1038/sj.npp.1301423.
   PubMed Web of Science ®Google Scholar
• Brody AL, Zorick T, Hubert R, Hellemann GS, Balali S, Kawasaki SS, McCreary C. Combination extended smoking cessation treatment plus home visits for smokers with schizophrenia: A randomized controlled trial. NICTOB. 2017;19:68–76. doi:10.1093/ntr/ntw190.
   PubMed Web of Science ®Google Scholar
• Brunette MF, Ferron JC, Gottlieb J, Devitt T, Rotondi A. Development and usability testing of a web-based smoking cessation treatment for smokers with schizophrenia. Internet Interv. 2016;4:113–119. doi:10.1016/j.invent.2016.05.003.
   PubMedGoogle Scholar
• Caponnetto P, Auditore R, Russo C, Cappello G, Polosa R. Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study. Int J Environ Res Public Health. 2013;10:446–461. doi:10.3390/ijerph10020446.
   PubMed Web of Science ®Google Scholar
• Cather C, Dyer MA, Burrell HA, Hoeppner B, Goff DC, Evins AE. An open trial of relapse prevention therapy for smokers with schizophrenia. J Dual Diagn. 2013;9:87–93. doi:10.1080/15504263.2012.749559.
   PubMed Web of Science ®Google Scholar
• Chou K-R, Chen R, Lee J-F, Ku C-H, Lu R-B. The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia. Int J NursStud. 2004;41:321–330. doi:10.1016/j.ijnurstu.2003.07.001.
   PubMed Web of Science ®Google Scholar
• Evins AE, Cather C, Pratt SA, Pachas GN, Hoeppner SS, Goff DC, Achtyes ED, Ayer D, Schoenfeld DA. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA. 2014;311:145–154. doi:10.1001/jama.2013.285113.
   PubMed Web of Science ®Google Scholar
• Evins AE, Cather C, Deckersbach T, Freudenreich O, Culhane MA, Olm-Shipman CM, Henderson DC, Schoenfeld DA, Goff DC, Rigotti NA, et al. A double-blind placebo controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol. 2005;25:218–225. doi:10.1097/01.jcp.0000162802.54076.18.
   PubMed Web of Science ®Google Scholar
• George TP, Vessicchio JC, Sacco KA, Weinberger AH, Dudas MM, Allen TM, Creeden CL, Potenza MN, Feingold A, Jatlow PI. A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biol Psychiatry. 2008;63:1092–1096. doi:10.1016/j.biopsych.2007.11.002.
   PubMed Web of Science ®Google Scholar
• George TP, Vessicchio JC, Termine A, Bregartner TA, Feingold A, Rounsaville BJ, Kosten TR. A placebo-controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry. 2002;52:53–61. doi:10.1016/S0006-3223(02)01339-2.
   PubMed Web of Science ®Google Scholar
• George TP, Ziedonis DM, Feingold A, Pepper WT, Satterburg CA, Winkel J, Rounsaville BJ, Kosten TR. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry. 2000;157:1835–1842. doi:10.1176/appi.ajp.157.11.1835.
   PubMed Web of Science ®Google Scholar
• Griffiths M, Wardle H, Orford J, Sproston K, Erens B. Gambling, alcohol, consumption, cigarette smoking and health: findings from the 2007 British gambling prevalence survey. Addict Res Theory. 2010;18(1):208–223. doi:10.3109/16066350902928569.
   Google Scholar
• Horst DW, Klein MW, Williams D, Werder SF. Extended use of nicotine replacement therapy to maintain smoking cessation in persons with schizophrenia. Neuropsychiatr Dis Treatment. 2005;1:349–355.
   PubMedGoogle Scholar
• Roll JM, Higgins ST, Steingard S, McGinley M. Use of monetary reinforcement to reduce the cigarette smoking of persons with schizophrenia: a feasibility study. Exp Clin Psychopharmacol. 1998;6:157–161. doi:10.1037//1064-1297.6.2.157.
   PubMed Web of Science ®Google Scholar
• Tidey JW, O'Neill SC, Higgins ST. Contingent Monetary reinforcement of smoking reductions with and without transdermal nicotine, in outpatients with schizophrenia. Exper Clin Psychopharmachol. 2002;10:241–246. doi:10.1037//1064-1297.10.3.241.
   PubMed Web of Science ®Google Scholar
• Weiner E, Ball MP, Buchholz AS, Gold JM, Evins AE, McMahon RP, Buchanan RW. Bupropion sustained release added to group support for smoking cessation in schizophrenia: a new randomized trial and a meta‐analysis. J Clin Psychiatry. 2012;73:95–102. doi:10.4088/JCP.10m06143gre.
   PubMed Web of Science ®Google Scholar
• Weiner E, Buchholz A, Coffay A, Liu F, McMahon RP, Buchanan RW, Kelly DL. Varenicline for smoking cessation in people with schizophrenia: a double-blind randomized pilot study. Schizophr Res. 2011;129:94–95. doi:10.1016/j.schres.2011.02.003.
   PubMed Web of Science ®Google Scholar
• Williams JM, Gandhi KK, Lu S-E, Kumar S, Shen J, Foulds J, Kipen H, Benowitz NL. Higher nicotine levels I schizophrenia compared with controls after smoking a single cigarette. Nicotine Tob Res. 2010;12:855–859. doi:10.1093/ntr/ntq102.
   PubMed Web of Science ®Google Scholar
• Ziedonis DM, George TP. Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull. 1997;23:247–254. doi:10.1093/schbul/23.2.247.
   PubMed Web of Science ®Google Scholar
• Whittemore R, Knalf K. Theintegrative review: update methodology. J Adv Nurs. 2005;52:546–553. doi:10.1111/j.1365-2648.2005.03621.x.
   PubMed Web of Science ®Google Scholar
• Cooper HM. The integrative research review: a systematic approach. Applied social research methods series. Vol. 2. Beverly Hills, CA: Sage; 1984.
   Google Scholar
• Cooper HM. Organizing knowledge synthesis: A taxonomy of literature reviews. Knowl Soc. 1988;1:104–126. doi:10.1007/BF03177550.
   Google Scholar
• D’Souza DC, Esterlis I, Carbuto M, et al. Lower B2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia. Am J Psychiatry. 2012;169:326–334. doi:10.1176/appi.ajp.2011.11020189.
   PubMed Web of Science ®Google Scholar
• Esterlis I, Ranganathan M, Bois F, Pittman B, Picciotto MR, Shearer L, Anticevic A, Carlson J, Niciu MJ, Cosgrove KP, et al. In vivo evidence for B2 nicotinic acetylcholine receptor subunit upregulation in smokers as compared with nonsmokers with schizophrenia. Biol Psychiatry. 2014;76:495. doi:10.1016/j.biopsych.2013.11.001.
   PubMed Web of Science ®Google Scholar
• Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2013;2:CD007253.
   PubMedGoogle Scholar
• Liaisons and staff. Clinical Practice Guideline Treating Tobacco Use and Dependence Update Panel, A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. public health service report. Am J Prev Med. 2008;35:158–176.
   PubMed Web of Science ®Google Scholar
• Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Cochrane Database Syst Rev. 2013;5:CD009329.
   PubMed Web of Science ®Google Scholar
• Bennett L, Grant A, Jones A, Bowley M, Heathcote-Elliott C, Ford C, Jones A, Lewis R, Munkley M, Owen C, et al. Models for Access to Maternal Smoking cessation Support (MAMSS): a study protocol of a quasi-experiment to increase the engagement of pregnant women who smoke in NHS Stop Smoking Services. BMC Public Health. 2014;14:1041.doi:10.1186/1471-2458-14-1041.
   PubMed Web of Science ®Google Scholar
• Banham L, Gilbody S. Smoking cessation in severe mental illness: what works? Addiction. 2010;105:1176–1189. doi:10.1111/j.1360-0443.2010.02946.x.
   PubMed Web of Science ®Google Scholar
• Evins AE, Culhane MA, Alpert JE, Pava J, Liese BS, Farabaugh A, Fava M. A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders. J Clin Psychopharmacol. 2008;28:660–666. doi:10.1097/JCP.0b013e31818ad7d6.
   PubMed Web of Science ®Google Scholar
• Callaghan RC, Veldhuizen S, Jeysingh T, et al.. Patterns of tobacco-related mortality among individuals diagnosed with schizophrenia, bipolar disorder, or depression. J. Psychiatr. Res. 2014;48(1):102–110.
   PubMed Web of Science ®Google Scholar
• Suvisaari J, Partti K, Viertiö S, Saarni SE, Lönnqvist J, Saarni SI, Härkänen T. Mortality and its determinants in people with psychotic disorder. Psychosom Med. 2013;75(1):60–67.
   PubMed Web of Science ®Google Scholar
• Kelly DL, McMahon RP, Wehring HJ, Liu F, Mackowick KM, Boggs DL, Warren KR, Feldman S, Shim J-C, Love RC, et al. Cigarette smoking and mortality risk in people with schizophrenia. Schizophrenia Bull. 2011;37:832–838. doi:10.1093/schbul/sbp152.
   PubMed Web of Science ®Google Scholar
• Evins AE, Cather C. Effective cessation strategies for smokers with Schizophrenia. Int Rev Neurobiol. 2015;124:133–147. doi:10.1016/bs.irn.2015.08.001.
   PubMed Web of Science ®Google Scholar
• Horst DW, Klein MW, Williams D, Werder SF. Extended use of nicotine replacement therapy to maintain smoking cessation in persons with schizophrenia. Neuropsychiatr Dis Treat. 2005;1:349–355.
   PubMedGoogle Scholar
• Hughes JR, Carpenter MJ. Does smoking reduction increase future cessation and decrease disease risk? A qualitative review. Nicotine Tob Res. 2006;8:739–749. doi:10.1080/14622200600789726.
   PubMed Web of Science ®Google Scholar
• McChargue DE, Gulliver SB, Hitsman B. Would smokers with schizophrenia benefit from a more flexible approach to smoking treatment? Addiction. 2002;97:785–793. doi:10.1046/j.1360-0443.2002.00064.x.
   PubMed Web of Science ®Google Scholar
• Marlatt GA, Larimer ME, Witkiewitz K. Harm reduction second edition pragmatic strategies for managing high-risk behaviors. 2nd ed. New York, NY: Guilford Press; 2011.
   Google Scholar
• Carter LP, Stitzer ML, Hanningfield JE, O'Connor RJ, Cummings KM, Hatsukami DK. Abuse liability assessment of tobacco products including potential reduced exposure products. Cancer Epidemiol Biomarkers Prev. 2009;18(12):3241–3262.
   PubMed Web of Science ®Google Scholar
• O’Connor RJ. Non-cigarette tobacco products: what have we learned and where are we headed? Tobacco Control. 2012;21(2):181–190.
   PubMed Web of Science ®Google Scholar
• FDA. 2016. FDA 101: Smoking Cessation Products”. U.S. Food and Drug Administration. Archived from the Original on 3 November 2018. Retrieved 28 June 2019.
   Google Scholar
• Department of Health. Equity and excellence: liberating the NHS. London, UK: TSO; 2010
   Google Scholar
• Beard E, McNeill A, Aveyard P. Association between use of nicotine replacement therapy for harm reduction and smoking cessation: a prospective study of English smokers. Tob Control. 2011;22:118–122. doi:10.1136/tobaccocontrol-2011-050007.
   PubMed Web of Science ®Google Scholar
• Campagna D, Amaradio MD, Sands MF, Polosa P. Respiratory infections and pneumonia: potential benefits of switching from smoking to vaping. Pneumonia. 2016;8:4. https://doi.org/10.1186/s41479-016-0001-2 doi:10.1186/s41479-016-42-2.
   Web of Science ®Google Scholar
• Polosa R, Morjaria J, Caponnetto P, Battaglia E, Russo C, Ciampi C, Adams G, Bruno C. Blood pressure control in smokers with arterial hypertension who switched to electronic cigarettes. IJERPH. 2016;13:1123. doi:10.3390/ijerph13111123.
   Google Scholar
• Cibella F, Campagna D, Caponnetto P, Amaradio MD, Caruso M, Russo C, Cockcroft DW, Polosa R. Lung function and respiratory symptoms in a randomized smoking cessation trial of electronic cigarettes. Clin Sci (Lond). 2016;130:1929–1937. 1 doi:10.1042/CS20160268.
   PubMed Web of Science ®Google Scholar
• Farsalinos KE, Romagna G, Tsiapras D, Kyrzopoulos S, Voudris V. Characteristics, perceived side effects and benefits of electronic cigarette use: a worldwide survey of more than 19,000 consumers. IJERPH. 2014;11:4356–4373. doi:10.3390/ijerph110404356.
   Google Scholar
• O'Brien B, Knight-West O, Walker N, Parag V, Bullen C. E-cigarettes versus NRT for smoking reduction or cessation in people with mental illness: secondary analysis of data from the ASCEND trial. Tob Induced Dis.. 2015;13:5. doi:10.1186/s12971-015-0030-2
   PubMed Web of Science ®Google Scholar
• Caponnetto P, Polosa R, Auditore R, Russo C, Campagna D. Smoking cessation with E-cigarettes in smokers with a documented history of depression and recurring relapses. IJCM. 2011;2:281–284. doi:10.4236/ijcm.2011.23046.
   Google Scholar